GLP-1 dose titration and the nutrition data worth checking before each increase

The FDA label for tirzepatide starts at 2.5 mg for four weeks, then increases to 5 mg. Further increases use increments of 2.5 mg after at least four weeks on the current dose, with maintenance-dose selection based on response and tolerability.³ On the standard Wegovy subcutaneous 2.4 mg pathway, semaglutide escalates from 0.25 mg across 16 weeks, with 2.4 mg beginning in week 17 and escalation delayed when a dose is not tolerated.¹ The current label also allows 1.7 mg maintenance and, for adults with obesity needing additional weight reduction, escalation to 7.2 mg after at least four weeks at 2.4 mg.¹ These schedules manage gastrointestinal tolerability. Intake, protein, and rate-of-loss trends provide additional nutrition context for the prescriber before an increase.

AI-assisted nutrition tracking can generate intake, protein, and rate-of-loss trends to bring to that medication review.

01Why semaglutide and tirzepatide use four-week minimum intervals

Semaglutide and tirzepatide use scheduled steps to reduce gastrointestinal adverse reactions, which occur most frequently during or shortly after dose escalation.⁶ Their labels direct dose decisions by response and tolerability rather than tracked food intake.¹³

Tirzepatide's four-week spacing also tracks its pharmacokinetics. The drug has an approximate five-day half-life and reaches steady-state concentration after four weeks of weekly dosing.³ Three doses on that ladder, 5 mg, 10 mg, and 15 mg, are recognized maintenance targets. The label directs maintenance-dose selection according to treatment response and tolerability.³ Nutrition trends can add context to that discussion.

02GLP-1 appetite suppression hides under-eating you cannot feel

In a controlled 30-person, 12-week mechanistic study that escalated once-weekly semaglutide to 1.0 mg, semaglutide reduced ad libitum energy intake at lunch, dinner, and evening snacks enough to produce a 24 percent reduction in total daily energy intake compared with placebo.² Reduced hunger and stronger fullness after small portions contributed to the difference.

That effect is part of the mechanism the drug is prescribed for. Lower hunger therefore cannot establish whether a person is meeting an individualized calorie or protein target. Measuring intake provides information that appetite alone cannot.

03GLP-1 GI side effects peak in the same weeks as dose increases

Gastrointestinal side effects are not evenly spread across a course of treatment. In pooled STEP 1 to 3 data, GI adverse events affected 72.9 percent of participants receiving semaglutide 2.4 mg versus 47.1 percent on placebo and occurred most often during or shortly after dose escalation. Median event duration was eight days for nausea, three days for diarrhea, and two days for vomiting.⁶ These symptoms can overlap the weeks before a scheduled dose decision. For the day-to-day version of managing that overlap, see Eating Through GLP-1 Side Effects.

Symptom tolerability and recorded protein intake answer different questions. Reviewing both gives the prescriber more information before the next scheduled step.

04Why lean mass loss makes nutrition monitoring relevant

The post hoc SURMOUNT-1 body composition substudy found that tirzepatide-treated participants lost about 15.9 kg of fat mass and 5.6 kg of lean mass over 72 weeks. Lean mass fell 10.9 percent from baseline versus 2.6 percent on placebo and accounted for roughly a quarter of total weight lost.⁴ A 2026 observational preprint reported greater relative lean-mass decline with tirzepatide than semaglutide by 1.1, 1.5, 1.3, and 2.0 percentage points at months 3, 6, 9, and 12, respectively.⁵

Protein intake and resistance training are recommended components of lean-mass preservation during GLP-1 therapy.⁷ The full protein and training framework for this population lives in How to Preserve Muscle on GLP-1 Medications, and the sex-specific version for active women managing menopause, cycle, and GLP-1s together is in Women's Fat Loss and Muscle Retention.

05The calorie, protein, and rate-of-loss checks before a GLP-1 dose increase

A titration decision is the prescriber's call, and dose changes require a prescription. A patient or coach can bring recent nutrition and symptom trends to that conversation. The prompts below are monitoring heuristics for clinician discussion, not validated clinical cutoffs.⁷

None of these trends makes the dosing decision by itself. Calorie and protein targets should account for body size, age, kidney function, treatment response, and other clinical risks.⁷ Rate-of-loss planning is covered in more depth in How Fast to Lose Fat. The same intake and rate-of-loss trends built during titration are the ones worth carrying into the opposite conversation, stopping the medication, where trial data show most people regain a large share of the weight within a year, covered in The Nutrition and Muscle Plan for Stopping a GLP-1.

06Why passive food logging catches the weeks you stop tracking on a GLP-1

All four signals require reasonably complete data. If manual food logs become incomplete, a lower-burden method such as photo capture or voice notes may preserve enough information for review.

The gain is having an intake trend to review before a dose decision. When to Trust vs. Override Your AI Nutrition Coach covers where automated tracking is reliable enough to act on and where a human still needs to check the output. For someone titrating a GLP-1, the useful output is a reviewable record of intake alongside symptoms, weight trend, treatment response, and tolerability.